1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015

Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 40 pages

Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015’, provides an overview of the Acute Lymphoblastic Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lymphoblastic Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphoblastic Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Lymphoblastic Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lymphoblastic Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lymphoblastic Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lymphoblastic Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Lymphoblastic Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Lymphoblastic Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acute Lymphoblastic Lymphoma - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Acute Lymphoblastic Lymphoma Overview 6
Therapeutics Development 7
Pipeline Products for Acute Lymphoblastic Lymphoma - Overview 7
Pipeline Products for Acute Lymphoblastic Lymphoma - Comparative Analysis 8
Acute Lymphoblastic Lymphoma - Therapeutics under Development by Companies 9
Acute Lymphoblastic Lymphoma - Therapeutics under Investigation by Universities/Institutes 10
Acute Lymphoblastic Lymphoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Acute Lymphoblastic Lymphoma - Products under Development by Companies 13
Acute Lymphoblastic Lymphoma - Products under Investigation by Universities/Institutes 14
Acute Lymphoblastic Lymphoma - Companies Involved in Therapeutics Development 15
EpiZyme, Inc. 15
Juno Therapeutics Inc. 16
Novartis AG 17
Zymeworks Inc. 18
Acute Lymphoblastic Lymphoma - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
EPZ-5676 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
JCAR-014 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
midostaurin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ZW-38 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Acute Lymphoblastic Lymphoma - Recent Pipeline Updates 35
Acute Lymphoblastic Lymphoma - Discontinued Products 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables

Number of Products under Development for Acute Lymphoblastic Lymphoma, H1 2015 7
Number of Products under Development for Acute Lymphoblastic Lymphoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Acute Lymphoblastic Lymphoma - Pipeline by EpiZyme, Inc., H1 2015 15
Acute Lymphoblastic Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2015 16
Acute Lymphoblastic Lymphoma - Pipeline by Novartis AG, H1 2015 17
Acute Lymphoblastic Lymphoma - Pipeline by Zymeworks Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Acute Lymphoblastic Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 35
Acute Lymphoblastic Lymphoma - Discontinued Products, H1 2015 38

List of Figures

Number of Products under Development for Acute Lymphoblastic Lymphoma, H1 2015 7
Number of Products under Development for Acute Lymphoblastic Lymphoma - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.